111 related articles for article (PubMed ID: 33812414)
1. [The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia].
Cao HQ; Tuo JB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):450-455. PubMed ID: 33812414
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
[TBL] [Abstract][Full Text] [Related]
3. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
[TBL] [Abstract][Full Text] [Related]
4. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
Micol JB; Duployez N; Boissel N; Petit A; Geffroy S; Nibourel O; Lacombe C; Lapillonne H; Etancelin P; Figeac M; Renneville A; Castaigne S; Leverger G; Ifrah N; Dombret H; Preudhomme C; Abdel-Wahab O; Jourdan E
Blood; 2014 Aug; 124(9):1445-9. PubMed ID: 24973361
[TBL] [Abstract][Full Text] [Related]
5. [Frequency and clinical features of ASXL2 gene mutation in acute myeloid leukemia patients with AML1- ETO fusion gene positive].
Zhao JX; Chen XH; Li JL; Pan J; Tan YH; Xu ZF; Ren FG; Zhang YF; Xu J; Li MQ; Li J; Zhang N; Chang JM; Wang XJ; Wang HW
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):676-81. PubMed ID: 27587249
[TBL] [Abstract][Full Text] [Related]
6. [Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene].
Cui P; Xu D; Xing T; Ren GH; Ma SM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):125-129. PubMed ID: 32027264
[TBL] [Abstract][Full Text] [Related]
7. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
Hartmann L; Dutta S; Opatz S; Vosberg S; Reiter K; Leubolt G; Metzeler KH; Herold T; Bamopoulos SA; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Hopfner KP; Graf A; Krebs S; Blum H; Middeke JM; Stölzel F; Thiede C; Wolf S; Bohlander SK; Preiss C; Chen-Wichmann L; Wichmann C; Sauerland MC; Büchner T; Berdel WE; Wörmann BJ; Braess J; Hiddemann W; Spiekermann K; Greif PA
Nat Commun; 2016 Jun; 7():11733. PubMed ID: 27252013
[TBL] [Abstract][Full Text] [Related]
8. ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells.
Redondo Monte E; Wilding A; Leubolt G; Kerbs P; Bagnoli JW; Hartmann L; Hiddemann W; Chen-Wichmann L; Krebs S; Blum H; Cusan M; Vick B; Jeremias I; Enard W; Theurich S; Wichmann C; Greif PA
Oncogene; 2020 Apr; 39(15):3195-3205. PubMed ID: 32115572
[TBL] [Abstract][Full Text] [Related]
9. [Genetic abnormalities in core binding factor acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
[TBL] [Abstract][Full Text] [Related]
10. RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature.
Lavallée VP; Lemieux S; Boucher G; Gendron P; Boivin I; Armstrong RN; Sauvageau G; Hébert J
Blood; 2016 May; 127(20):2498-501. PubMed ID: 26968532
[No Abstract] [Full Text] [Related]
11. [Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].
Wu TM; Xue SL; Li Z; Yu JQ; Wang J; Wang BR; Wan CL; Shen XD; Qiu QC; Bao XB; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):646-653. PubMed ID: 34547870
[No Abstract] [Full Text] [Related]
12. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.
Micol JB; Pastore A; Inoue D; Duployez N; Kim E; Lee SC; Durham BH; Chung YR; Cho H; Zhang XJ; Yoshimi A; Krivtsov A; Koche R; Solary E; Sinha A; Preudhomme C; Abdel-Wahab O
Nat Commun; 2017 May; 8():15429. PubMed ID: 28516957
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for transcription factor ZBTB7A recognition of DNA and effects of ZBTB7A somatic mutations that occur in human acute myeloid leukemia.
Ren R; Horton JR; Chen Q; Yang J; Liu B; Huang Y; Blumenthal RM; Zhang X; Cheng X
J Biol Chem; 2023 Feb; 299(2):102885. PubMed ID: 36626981
[TBL] [Abstract][Full Text] [Related]
14. The genomic landscape of core-binding factor acute myeloid leukemias.
Faber ZJ; Chen X; Gedman AL; Boggs K; Cheng J; Ma J; Radtke I; Chao JR; Walsh MP; Song G; Andersson AK; Dang J; Dong L; Liu Y; Huether R; Cai Z; Mulder H; Wu G; Edmonson M; Rusch M; Qu C; Li Y; Vadodaria B; Wang J; Hedlund E; Cao X; Yergeau D; Nakitandwe J; Pounds SB; Shurtleff S; Fulton RS; Fulton LL; Easton J; Parganas E; Pui CH; Rubnitz JE; Ding L; Mardis ER; Wilson RK; Gruber TA; Mullighan CG; Schlenk RF; Paschka P; Döhner K; Döhner H; Bullinger L; Zhang J; Klco JM; Downing JR
Nat Genet; 2016 Dec; 48(12):1551-1556. PubMed ID: 27798625
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
[TBL] [Abstract][Full Text] [Related]
16. [The impact of KIT and other concomitant gene mutations on the prognoses of patients with core-binding factor acute myeloid leukemia].
Wang F; Wang W; Liu M; Zhang Y; Chen X; Yuan LL; Ma XL; Nie DJ; Wang MY; Zhang Y; Zhang W; Liu MY; Liu HX
Zhonghua Yi Xue Za Zhi; 2020 Jan; 100(3):225-229. PubMed ID: 32008291
[No Abstract] [Full Text] [Related]
17. Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
Parsa-Kondelaji M; Ayatollahi H; Rostami M; Sheikhi M; Barzegar F; Afzalaghaee M; Moradi E; Sadeghian MH; Momtazi-Borojeni AA
J Cell Mol Med; 2022 Jul; 26(13):3797-3801. PubMed ID: 35692075
[TBL] [Abstract][Full Text] [Related]
18. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
19. [Clinical features and survival analysis in non-M(3) acute myeloid leukemia patients with ASXL1 gene mutation].
Jia WB; Liu JT; Yang XY; Wu HY; Wei YH; Can C; Wang RQ; He N; Gu CY; Ma DX; Ji CY
Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):833-840. PubMed ID: 36709197
[No Abstract] [Full Text] [Related]
20. Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21).
Duployez N; Micol JB; Boissel N; Petit A; Geffroy S; Bucci M; Lapillonne H; Renneville A; Leverger G; Ifrah N; Dombret H; Abdel-Wahab O; Jourdan E; Preudhomme C
Leuk Lymphoma; 2016; 57(1):199-200. PubMed ID: 25856206
[No Abstract] [Full Text] [Related]
[Next] [New Search]
